Extracellular signals perceived by Gprotein-coupled receptors are transmittedv ia Gproteins, and subsequent intracellular signaling cascades result in ap lethora of physiological responses. The natural product cyclic depsipeptides YM-254890 and FR900359a re the only knownc ompounds that specifically inhibit signalingm ediated by the G q subfamily.I nt his study we exploit an ewly developed synthetic strategy for this compound class in the design,s ynthesis, and pharmacological evaluation of eight new analogues of YM-254890. These structureactivity relationship studies led to the discovery of three new analogues,Y M-13, YM-14, and YM-18, which displayed potent and selective G q inhibitory activity.T his provides pertinenti nformationf or the understanding of the G q inhibitory mechanism by this class of compounds and importantly provides ap athway for the development of labeled YM-254890 analogues.
Heterotrimeric Gproteins are GTP/GDP-binding proteins made up of three subunits, a, b,a nd g,w hich are keys ignal-transducing molecules activated by Gprotein-coupled receptors (GPCRs). [1, 2] The propagation of Gprotein-mediated signals share ac ommonm echanism:T he ligand-activated GPCR engages with Gproteins,w hich leads to the release of GDP from the Gprotein a subunit (Ga). Intracellular GTP is bound to the nucleotide-free Gprotein, allowing dissociation of the Ga subunit from the Gbg dimer and GPCR,l eadingt ot he regulation of downstream effectors such as ion channels and phospholipase Ct oi nduce cellular responses. [3] Heterotrimeric Gproteins are divided into four different classes, G s ,G i/o ,G q/11 and G 12/13 , which mediate various signaling pathways.
GPCRs are encoded by more than 800 genes, constitute the third-largest gene family in the human genome, [4] play important roles in detecting environmental stimuli,a nd are involved in ap lethora of diseases. [5] It is estimated that approximately 40 %o fa ll current drugs targetG PCRs. [6, 7] In contrast to GPCRs, the precise function and regulation of Gproteins is muchl ess well understood,w hich,t oalarge degree, is due to lack of se-lective and potent inhibitors of Gproteins.O nly very few compoundsh ave been shownt os electively modulate Gprotein function. Notably,p ertussis toxin and cholera toxin [8] [9] [10] are known as selective modulators of G i and G s proteins,r espectively.
The cyclic depsipeptides YM-254890 (1,F igure 1a)i solated from Chromobacterium sp. QS3666, [11] andF R900359( 2,F igure 1a)i solated from the plant Ardisiac renata, [12, 13] are the only known compounds that specifically inhibit G q signaling. They were originally discovered due to their inhibition of ADPinduced platelet aggregation, [14, 15] but are now important pharmacological tools in studies of G q -mediated cell responses. Moreover,t here is increasing interesti nt he potential development of such molecules as therapeutic agents, particularly for variousforms of cancer. [16, 17] The molecular basis of how YM-254890 blocksG q signaling was revealed by an X-ray crystal structureo facomplexb etween YM-254890 and ac himeric G i/q protein ( Figure 1b ). [18] This showed that G q -mediated inhibition by YM-254890i sa chieved by stabilizing an inactiveG DP-bound form of G q ,w hich inhibitst he fundamentalG DP/GTP exchange of the Gprotein.
Although there is great interesta nd demand for studying G q -mediated signaling using G q protein inhibitors, noneo f these inhibitors had been generally available. [19] This spurred great interest in generating them by total synthesis, as illustrated by ac ompetition for generating 1mgo fY M-254890 (https://www.innocentive.com/ar/challenge/9933017), as well as recent efforts towardt he total synthesis. [20, 21] Very recently, the first total synthesis of YM-254890 and FR900359w as achieved, which also provided sufficient material for verification of the proposed chemical structure, thorough chemical and pharmacological characterization. [22] Thus with av ersatile synthetic approach in hand, we were interested in the design ands ynthesis of analogues to provide molecular insighti nto the structurale lements required forb iological activity,a sw ell as to provide necessary structure-activity relationship (SAR) studies. Because YM-254890 [23] and FR900359a re nearly equipotent, and FR900359i ss lightly more synthetically challenging, [22] we used YM-254890 as at emplate. YM-254890 comprises seven amino acids (alanine (Ala), threonine (Thr), N-methylalanine (N-MeAla), N-methyldehydroalanine (N-MeDha), two b-hydroxyleucines (b-HyLeu-1 and b-HyLeu-2), and N,O-dimethylthreonine (N,O-Me 2 Thr)), as well as an a-hydroxy acid( d-3-phenyllactic acid (d-Pla)), three ester bonds, and two acetyl groups (1, Figure 1a ). [23] Not surprisingly,only very sparse SAR studies have been performed so far,u sing either structurally relatedn atural products (YM-254891, YM-254892, and YM-280193), [24] semisynthetic hydrogenated analogues( YM-385780 andY M-385781), [24] as ynthesized fragmentW U-07047 [20] or analogues YM-1-YM-10 [22] (Supporting Information Figure 1 ). In particular, the structural integrity of YM-254890 and the N-MeDha residue are critical for biological activity,a nd changes in the backbonea nd N-MeDhaa re generally not tolerated. We were therefore interested in examining the N-MeAla and Ala residues of YM-254890. Thus, herein we report the design and synthesis of eight new YM-254890 analogues generatedb yt otal synthesis and modification of the N-MeAla and Ala residues of YM-254890 ( Figure 2 ). The analogues were subsequently examined for their Gprotein inhibitory potency and selectivity by evaluation of pharmacological activity at G q -, G i -, and G s -mediated signaling.
In our systematic evaluation of N-MeAla and Ala, we first designed four analogues replacing N-MeAla with residues in which steric hindrance was either increased, N-methylvaline (N-MeVal) or decreased, N-methylglycine (N-MeGly) (YM-11( 3)a nd YM-12 (4), respectively,F igure 2). Moreover,w ee xamined the importance of stereochemistry by introducing N-methyl-d-alanine (N-Me-d-Ala) and effects of introducing an aromatic elec-tron-rich moiety, N-methylphenylalanine (N-MePhe) (YM-13 (5) and YM-14 (6), respectively,F igure 2). For the other residue, Ala, we introduced principally similars ubstituents by incorporation of valine (Val), glycine (Gly), d-alanine (d-Ala), and phenylalanine (Phe) (YM-15-YM-18 (7-10), respectively, Figure 2 ).
In our retrosynthetica nalysis (Scheme 1), which is inspired by our building-block approach used in the synthesis of YM-254890, [22] the macrocyclization site was chosen between the N-methylated residue of interesta nd the b-HyLeu residue. Thus, al inear precursor 11 should be generated with the N-MeDhar esidue to be accessedf rom the resin-boundd epsipeptide 12 using an StBu-protected cysteinederivative as aprecursor (Scheme 1). [25] Ak ey feature is that 12 is generated from three building blocks:r esin-bound 13 that would contain the residues where modifications would be introduced,a sw ella s two ester-containing building blocks 14 and 15 that would be the same for all analogues.
The common buildingb locks 14 and 15 were prepared in good yield as previously reported. [22] First, resin-bound peptides 13 a-h were synthesized according to standards olidphase peptide synthesis (SPPS) procedures using a2 -chlorotrityl resin [26] and N-MeCys(StBu)-OH [27] as the N-MeDha precursor. The variable residues were the first two residues to be anchored to the solid support (Scheme 2). Subsequent coupling of 14 furnished the resin-bound depsipeptides 16 a-h (Scheme 2). Next, 15 was introduced, providing the linear resin-bound depsipeptides 12 a-h.A fter the assembly of all residues,the N-MeDha residue was generated through areduction-bisalkylation-elimination process [25, 28] to give resin-bound compounds 17 a-h.T he linear precursors of the desired analogues, 11 a-h,w ere then accessed by release from the resin and concomitant removal of the O-a nd N-Boc groups. Finally, the crude analogues 3-10 (Scheme2)w ere generated by macrolactamization of 11 a-h,c arried out at highly dilutedc oncentrationsw ith HATU/collidine as coupling reagent/base pair, which was the "rate-limiting" synthetic step, with yields of 10-20 %. All analogues were subsequently purified by semi-prepa- The inhibitory effect of YM-254890 as well as the eight new analogues on G q -mediated signaling( Ta ble 1) was evaluated in Chinese hamster ovary (CHO) cells that stably express the human M 1 muscarinic receptor.T he M 1 receptor is activated by carbachol, which leads to the G q -mediated generation of inositol monophosphate (IP 1 ), and G q inhibition is determined as ad ecrease in IP 1 accumulation. To address the selectivity of these analogues we also examined the compoundsf or their ability to inhibit G s -a nd G i -mediated signaling (SupportingI nformation Ta ble 1). Thisw as accomplishedb ye xamining the inhibition of isoproterenol-induced cyclic adenosine monophosphate (cAMP) productioni nh uman embryonic kidney www.chemmedchem.org (HEK) 293 cells that endogenously expresst he b 2 adrenergic receptor (G s signaling) and the inhibition of glutamic acid induced cAMP reduction in CHO cells that stably expresst he rat metabotropic glutamater eceptor 2( mGlu2)r eceptor (G i signaling).
In general, we observed that all analogues selectively inhibited G q -mediated signaling, as no inhibitory effect on G s or G i signaling was observed (Supporting Information Table 1 ). Moreover,c hanging the Ala residue next to N-MeDha (7-10) led to more dramatic changes than modifying the N-MeAla residue (3-6)( Ta ble 1).
Interestingly,t he most dramatic change in inhibitory activity was observed when changing the stereochemistry of l-Ala to d-Ala (9)l eadingt oas triking 244-fold loss of potency,c learly underlining the requirement for an appropriate stereochemical arrangement at this position. Removing the side chain at the same positionb yi ntroducing aG ly residue (8)l ed to a1 7-fold decreasei np otency, whereas introducing more bulk by aV al residue (7) d ecreased potency 6-fold relative to YM-254890. Notably,i ntroducing Phe (10)l ed to al ess than 2-fold change in potency,t hereby being essentially equipotent to YM-254890. From the X-ray crystal structureo fY M-254890, the Phe residue of 10 appearst or eside outside the binding pocket and to not interact directly with the Gprotein (Figure 3a) .
Modifying the N-MeAla residue in general did not affect potency to the same degree as observed forA la, and all analoguesw ere within 3-fold of the potencyo fY M-254890. Most interestingly was the analogue in which N-MePhe was introduced (6) , which gratifyingly wase quipotent to YM-254890 and the most potent analogue of YM-254890 generated so far. Similar to the situation for 10,t he N-MePhe residue in 6 is positioned at the exterior of the G q protein with only minor or no contacts with the protein (Figure 3b ). In addition, and in very stark contrastt ot he neighboring position, introducing N-Me-d-Ala (5)a lso led to less than 2-fold change in potency, showingt hat at this position stereochemistry is not nearly as important.
Therefore, larger side chains can replace both Ala and N-MeAla residues. This agreesw ith the YM-254890/G q/i X-ray crystal structure, in which the sidec hains of these residues do not undergo direct interaction with the Gprotein [18] (Figure 1b ). This suggests that it might be possible to introduce larger substituents in this region, which could eventually pave the way for af luorescently labeled version of YM-254890, for example.
In summary,w eh ave designeda nd prepared ac ollection of eight structurally and stereochemically diversea nalogues of YM-254890 using an efficient synthetic protocol that uses ac ombinationo fs olid-and solution-phases ynthesis. The analogues were designed to probe the importance of changes in the N-MeAla and Alaresidues of YM-254890 for selective inhibition of G q -mediated signaling.T he biological evaluation of the eight analogues, YM-11t oY M-18, providedi mportant SAR information and notably resulted in the discovery of three new analogues,Y M-13, YM-14, and YM-18, which are equipotent and selective G q signaling inhibitors compared with YM-254890.
In general it has proven very difficult to improveo re ven maintain the potencyo fY M-254890 upon changingt he structure, andt hus it is particularly promising that YM-18, in which an aromatic moiety,P he, has been introduced,i se quipotent to YM-254890. This providesv ery important insightr egarding where to introduce, for example, cross-linking moieties or fluorescent groups for further applications of the YM-254890 compounds. Table 1 . Inhibition of G q -mediateds ignalingb y3-10. [a] CompdIC 50 [mm] [b] 95 %CI[mm] [c] pIC 50 AE SEM [d] YM-254890 (1) 
